- Anixa Biosciences (ANIX, Financial) receives a Notice of Allowance from the USPTO for its CAR-T technology patent.
- The patent is exclusively licensed to Anixa from The Wistar Institute and focuses on solid tumor treatment.
- The CAR-T technology is being tested in clinical trials at Moffitt Cancer Center for recurrent ovarian cancer.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company dedicated to cancer treatment and prevention, has announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application related to its chimeric antigen receptor-T cell (CAR-T) technology. This patent covers essential methods and compositions crucial to Anixa's CAR-T approach, which is engineered to tackle challenges in applying CAR-T therapies to solid tumors.
The patent rights were granted to The Wistar Institute and have been exclusively licensed to Anixa Biosciences. The innovative CAR-T technology is currently undergoing clinical trials at Moffitt Cancer Center, centered on treating patients with recurrent ovarian cancer. This reinforces Anixa’s commitment to advancing immuno-oncology, potentially signaling a breakthrough in the field.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, emphasized the importance of securing foundational patent protection, which is critical for the future development of novel immunotherapies capable of yielding transformative outcomes for cancer patients. Anixa's strategic collaboration with renowned research institutions further exemplifies its approach to leveraging emerging technologies for developing groundbreaking solutions in the fight against cancer.
